Rhinomed Ltd
ASX:RNO
Rhinomed Ltd
Cash from Financing Activities
Rhinomed Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rhinomed Ltd
ASX:RNO
|
Cash from Financing Activities
AU$5.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Financing Activities
-AU$431.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Financing Activities
AU$3.6m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-18%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Financing Activities
AU$36.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
46%
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Financing Activities
-AU$11.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Financing Activities
AU$231.6k
|
CAGR 3-Years
-70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rhinomed Ltd's Cash from Financing Activities?
Cash from Financing Activities
5.5m
AUD
Based on the financial report for Jun 30, 2023, Rhinomed Ltd's Cash from Financing Activities amounts to 5.5m AUD.
What is Rhinomed Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
10%
Over the last year, the Cash from Financing Activities growth was -13%. The average annual Cash from Financing Activities growth rates for Rhinomed Ltd have been -23% over the past three years , 10% over the past five years , and 10% over the past ten years .